Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin detemir

Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.

DRUG

insulin aspart

Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.

Trial Locations (32)

1000

Novo Nordisk Investigational Site, Skopje

1083

Novo Nordisk Investigational Site, Budapest

1606

Novo Nordisk Investigational Site, Sofia

2600

Novo Nordisk Investigational Site, Glostrup Municipality

3501

Novo Nordisk Investigational Site, Miskolc

5000

Novo Nordisk Investigational Site, Odense

5800

Novo Nordisk Investigational Site, Pleven

6000

Novo Nordisk Investigational Site, Kolding

9010

Novo Nordisk Investigational Site, Varna

15018

Novo Nordisk Investigational Site, Prague

20100

Novo Nordisk Investigational Site, Turku

31059

Novo Nordisk Investigational Site, Toulouse

34093

Novo Nordisk Investigational Site, Istanbul

34662

Novo Nordisk Investigational Site, Altunizade-Istanbul

35340

Novo Nordisk Investigational Site, Izmir

53203

Novo Nordisk Investigational Site, Pardubice

60220

Novo Nordisk Investigational Site, Seinäjoki

75015

Novo Nordisk Investigational Site, Paris

77520

Novo Nordisk Investigational Site, Olomouc

90029

Novo Nordisk Investigational Site, Oulu

117036

Novo Nordisk Investigational Site, Moscow

119049

Novo Nordisk Investigational Site, Moscow

125373

Novo Nordisk Investigational Site, Moscow

193144

Novo Nordisk Investigational Site, Saint Petersburg

00029

Novo Nordisk Investigational Site, Helsinki

80-211

Novo Nordisk Investigational Site, Gdansk

25-734

Novo Nordisk Investigational Site, Kielce

01-184

Novo Nordisk Investigational Site, Warsaw

07059

Novo Nordisk Investigational Site, Antalya

AB25 2ZG

Novo Nordisk Investigational Site, Aberdeen

DD1 9SY

Novo Nordisk Investigational Site, Dundee

NR4 7UY

Novo Nordisk Investigational Site, Norfolk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00623194 - Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689 | Biotech Hunter | Biotech Hunter